LOXO-783

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

Breast CancerHealthy

Phase 1

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Active, not recruitingNCT05307705

Eli Lilly and CompanyBreast Cancer

Start: 2022-05-11End: 2026-12-01Updated: 2026-03-27

A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

CompletedNCT05894928

Eli Lilly and CompanyHealthy

Start: 2023-06-07End: 2023-07-09Updated: 2023-09-26

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

CompletedNCT06028425

Eli Lilly and CompanyHealthy

Start: 2023-09-01End: 2023-12-23Updated: 2024-07-22

A Study of [14C]-LOXO-783 in Healthy Adult Participants

CompletedNCT06102512

Eli Lilly and CompanyHealthy

Start: 2023-10-23End: 2024-01-17Updated: 2024-07-22

Related Papers

Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study

Clinical Cancer Research2025-06-131 citations

Abstract 5977: Identification and characterization of an allosteric and mutant-selective PI3Kα inhibitor

Cancer Research2025-04-21

Abstract P4-08-02: LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3Kα H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3Kα H1047R-mutant breast cancer models

Cancer Research2023-03-019 citations

Abstract OT3-08-01: A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)

Cancer Research2023-03-018 citations